Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting

Nov. 6, 2018 22:31 UTC

MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc., a provider of advanced genomic sequencing and analytics for immuno-oncology, today announced that the company, along with one of their collaborators, Dr. Sekwon Jang of the Inova Cancer Center, will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.

Following is a list of abstracts that will be presented at the meeting.

 

Rapid Oral Abstract Presentation Session

Session     Title & Presenter    

Day & Time

    Location
Rapid Oral Abstracts    

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Presenter: Sekwon Jang, MD
Director, Melanoma and Cutaneous Oncology Therapeutics and Research
Inova Melanoma and Skin Cancer Center

   

November 9:
1:40 pm

    204ABC
 

Scientific Poster Presentations

Poster Number & Session     Title & Presenter     Day & Time     Location

P13
Biomarkers and Immune Monitoring

   

Molecular profiling of anti-PD-1 treated melanoma patients reveals importance of assessing neoantigen burden and tumor escape mechanisms for clinical treatment
Presenter: Charles W. Abbott, PhD

   

November 9:
12:45pm-2:15pm
and
6:30pm-8:00pm

    Hall E

P151
Cancer Vaccines, Personalized Vaccines and Technologies, Personalized Medicine

   

Improving neoantigen identification for therapeutic and diagnostic use in immuno-oncology using mass spectrometry and machine learning
Presenter: Sean M. Boyle, PhD

   

November 9:
12:45pm-2:15pm
and
6:30pm-8:00pm

    Hall E

P78
Biomarkers and Immune Monitoring

   

More sensitive identification of T-cell receptor beta rearrangements with an augmented transcriptome method
Presenter: Eric Levy, PhD

   

November 10:
12:20pm-1:50pm
and
7:00pm-8:30pm

    Hall E
                   

Personalis will also be exhibiting during the conference (Booth #617). Representatives will be available to answer questions about the company’s cancer immunogenomics services.

About Personalis, Inc.

Personalis, Inc. is a leading precision medicine company focused on advanced NGS-based services for immuno-oncology and cancer for clinical trials and translational research. The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile and each tumor’s unique immune microenvironment for immuno-oncology applications. The company’s Clinical Laboratory is GxP aligned as well as CLIA’88 and CAP accredited. Personalis is differentiated by advanced sequencing assays, algorithms and content for neoantigen characterization, customer regulatory support, and more. Visit our website at www.personalis.com and follow @PersonalisInc.

Contacts

for Personalis:
Jennifer Havlek, 650-752-1300
pr@personalis.com
www.personalis.com

 
 

Source: Personalis, Inc.

Back to news